Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review

Journal of Clinical Psychiatry

Volumn 67, Issue 4, 2006, Pages 600-610

  Dell'Osso, Bernardo ^a   Nestadt, Gerald ^b   Allen, Andrea ^a   Hollander, Eric ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

CLINICAL TRIAL; COMORBIDITY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MEDLINE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS;

EID: 33646796353     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0411     Document Type: Review

References (67)

1. Karno M, Golding JM, Sorenson SB, et al. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 1988;45:1094-1099
2. Zohar J, Insel TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment and pathophysiology. Biol Psychiatry 1987;22:667-687
3. Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990;47:577-585
4. Insel TR, Mueller EA, Alterman I, et al. Obsessive-compulsive disorder and serotonin: is there a connection? Biol Psychiatry 1985;20:1174-1188
5. Thoren P, Asberg M, Cronholm B, et al. Clomipramine treatment of obsessive-compulsive disorder, 1 : a controlled clinical trial. Arch Gen Psychiatry 1980;37:1281-1285
6. Asberg M, Thoren P, Bertilsson L. Clomipramine treatment of obsessive disorder: biochemical and clinical aspects. Psychopharmacol Bull 1981;18:13-21
7. Zohar J, Insel TR, Zohar-Kadouch RC, et al. Serotonergic responsivity in obsessive-compulsive disorder: effect of chronic clomipramine treatment. Arch Gen Psychiatry 1988;45:167-172
8. Montgomery SA. Pharmacological treatment of obsessive-compulsive disorder. In: Hollander E, Zohar J, Marazziti D, et al, eds. Current Insights in Obsessive-Compulsive Disorder. Chichester, UK: Wiley & Sons; 1994:215-226
9. Greist JH, Jefferson JW, Kobak KH, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:53-60
10. Piccinelli M, Pini S, Bellantuono C, et al. Efficacy of drug treatment in obsessive-compulsive disorder. Br J Psychiatry 1995;166:424-443
11. Fineberg N. Refining treatment approaches in obsessive-compulsive disorder. J Clin Psychopharmacol 1996;11(suppl 5):13-22
12. Sasson Y, Zohar Y. New developments in obsessive-compulsive disorder research: implications for clinical management. J Clin Psychopharmacol 1996;11(suppl 5):3-12
13. Hollander E, Fay M, Cohen B, et al. Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings. Am J Psychiatry 1988;145:1015-1017
14. Roseboom PH, Kalin NH. Neuropharmacology of venlafaxine. Depress Anxiety 2000;12(suppl 1):20-29
15. Stahl SM. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 2nd ed. Cambridge, UK: Cambridge University Press; 2000
16. Shelton RC. The dual-action hypothesis: does pharmacology matter? J Clin Psychiatry 2004;65(suppl 17):5-10
17. Denys D, van der Wee N, van Megen H, et al. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 2003;23:568-575
18. Denys D, van der Wee N, van Megen H, et al. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry 2004;65:37-43
19. Albert U, Aguglia E, Maina G, et al. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry 2002;63:1004-1009
20. Yaryura-Tobias JA, Nerizoglu FA. Venlafaxine in obsessive-compulsive disorder [letter]. Arch Gen Psychiatry 1996;53:653-654
21. Hollander E, Freidberg J, Wasserman S, et al. Venlafaxine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2003;64:546-550
22. Sevincok L, Uygur B. Venlafaxine in open-label treatment of patients with obsessive-compulsive disorder [letter]. Aust N Z J Psychiatry 2002;36:817
23. Rauch SL, O'Sullivan RL, Jenicke MA. Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases. J Clin Psychopharmacol 1996;16:81-84
24. Marazziti D. Venlafaxine treatment of obsessive-compulsive disorder: case reports. CNS Spectr 2003;8:421-422
25. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, 1: development, use and reliability. Arch Gen Psychiatry 1989;46:1006-1011
26. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health: 1976;218-222
27. Murphy DL, Zohar J, Benkelfat C, et al. Obsessive-compulsive disorder as a serotonin subsystem-related behavioral disorder. Br J Psychiatry 1989;155:15-24
28. Katz RJ, DeVeaugh-Geiss J, Landau P. Clomipramine in obsessive-compulsive disorder. Biol Psychiatry 1990;28:401-414
29. Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:730-738
30. Mundo E, Rouillon F, Figura ML, et al. Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Hum Psychopharmacol 2001;16:461-468
31. Koran LM, McElroy SL, Davidson JR, et al. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol 1996;16:121-129
32. Milanfranchi A, Ravagli S, Lensi P, et al. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1997;12:131-136
33. Freeman CP, Trimble MR, Deakin JF, et al. Fluvoxamine versus clomipramine in the treatment of obsessive-compulsive disorder: a multicenter, randomized, double-blind, parallel-group comparison. J Clin Psychiatry 1994;55:301-305
34. Smeraldi E, Erzegovesi S, Bianchi L, et al. Fluvoxamine vs clomipramine treatment in obsessive-compulsive disorder. New Trends Exp Clin Psychiatry 1992;8:63-66
35. Pigott T, Pato M, Berstein S, et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1990;47:926-932
36. Lopez-Ibor JJ Jr, Saiz J, Cottraux J, et al. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmacol 1996;6:111-118
37. Abramowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol 1997;65:44-52
38. Eddy KT, Dutra L, Bradley R, et al. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 2004;24:1011-1030
39. Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol 2002;22:309-317
40. Fernandez Cordoba E, Lopez-Ibor AJ. Use of monochlorimipramine in psychiatric patients who are resistant to other therapy [in Spanish]. Actas Luso Esp Neurol Psiquiatr 1967;26:119-147
41. Van Renynghe de Voxvrie. Use of anafranil (G-34586) in obsessive neurosis [in French]. Acta Neurol Psychiatr Belg 1968;68:787-792
42. Ananth J. Clomipramine: an antiobsessive drug. Can J Psychiatry 1986;31:253-258
43. Insel TR. New Findings in Obsessive-Compulsive Disorder. Washington, DC: American Psychiatric Press; 1984
44. Leonard H, Swedo S, Rapaport JL, et al. Treatment of childhood obsessive-compulsive disorder with clomipramine and desmethylimipramine: a double-blind crossover comparison. Psychopharmacol Bull 1988;24:93-95
45. DeVeaugh-Geiss J, Landau P, Katz R. Treatment of obsessive-compulsive disorder with clomipramine. Psychiatr Ann 1989;19:97-101
46. Ananth J, Pecknold JC, van den Steen N, et al. Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Prog Neuropsychopharmacol 1981;5:257-262
47. Insel TR, Murphy DL, Cohen RM, et al. Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983;40:605-612
48. Mavissakalian M, Michelson L. Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? J Nerv Ment Dis 1983;171:301-306
49. Pato MT, Chakravorty S. Discontinuation and long-term treatment of obsessive-compulsive disorder. In: Jenike MA, Baer L, Minichiello WE, eds. Obsessive-Compulsive Disorders: Practical Management. St. Louis, Mo: Mosby; 1998:625-646
50. Koran LM, Sallee FR, Pallanti S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1997;154:396-401
51. Fallon BA, Liebowitz MR, Campeas R, et al. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine. Arch Gen Psychiatry 1998;55:918-924
52. Bisserbe JC, Lane RM, Flament SM, et al. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. Eur Psychiatry 1997;153:1450-1454
53. Zohar J, Judge R, and the OCD Paroxetine Study Investigators. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry 1996;169:468-474
54. Mavissakalian M, Turner SM, Michelson L. Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? Am J Psychiatry 1985;142:572-576
55. Montgomery SA. Clomipramine in obsessional neurosis: a placebo controlled trial. Pharmaceutical Medicine 1980;1:189-192
56. Zohar J, Insel TR. Drug treatment of obsessive-compulsive disorder. J Affect Disord 1987;13:193-202
57. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396-404
58. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241
59. Wilens TE, Biederman J, Spencer TJ. Venlafaxine for adult ADHD [letter]. Am J Psychiatry 1995;152:1099-1100
60. Findling RL, Schwartz MA, Flannery DJ, et al. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry 1996;57:184-189
61. Entsuah R, Zhang J. Rates of complete somatic symptom resolution among depressed patients treated with venlafaxine or SSRI [poster]. Presented at the 26th annual meeting of the Collegium Internationale Neuropsychopharmacologicum; June 20-24, 2004; Paris, France
62. Entsuah R, Zhang J. Rates of complete symptom resolution among depressed patients treated with venlafaxine or SSRI [poster]. Presented at the 26th annual meeting of the Collegium Internationale Neuropsychopharmacologicum; June 20-24, 2004; Paris, France
63. Entsuah R. Complete remission of individual symptoms of depression resolution: a comparison of venlafaxine, SSRI, and placebo [poster]. Presented at the 26th annual meeting of the Collegium Internationale Neuropsychopharmacologicum; June 20-24, 2004; Paris, France
64. De Nayer A, Geerts S, Ruelens L, et al. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol 2002;5:115-120
65. Silverstone PH, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry 2001;62:523-529
66. Silverstone PH, Ravindran A, for the Venlafaxine XR 360 Study Group. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry 1999;60:22-28
67. Pallanti S, Hollander E, Bienstock C, et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002;5:181-191